Clinical Trials on Residual in Belgium

Total 12 results

Université Libre de Bruxelles

Completed

Can we Antagonize Mivacurium With Neostigmine ?

Neostigmine | Mivacurium | Residual Paralysis

Belgium
Onze Lieve Vrouw Hospital
Merck Sharp & Dohme LLC

Completed

Postoperative Residual Curarisation at Arrival in the Post-anesthesia Care Unit

Postoperative Hypoxemia | Postoperative Residual Curarisation | Postoperative Airway Obstruction

Belgium
Onze Lieve Vrouw Hospital

Completed

Postoperative Residual Curarization in 2018

Postoperative Residual Curarization

Belgium
Medicontur Medical Engineering Ltd
Medevise Consulting

Recruiting

Prospective Multicenter Clinical Study on the Visual and Refractive Outcomes and Safety Outcomes Following Implantation of an AddOn Intraocular Lens in Previously Pseudophakic Eyes

Refractive Errors | Presbyopia | Residual Astigmatism

Belgium, France, Spain, United Kingdom
Onze Lieve Vrouw Hospital

Completed

Postoperative Residual Paralysis After Cardiac Surgery

Postoperative Residual Curarization

Belgium
University Hospital, Ghent

Completed

Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer (OvIP1)

Ovarian Cancer | Primary Peritoneal Cancer

Belgium
Prof. Christina Peters
Amgen

Terminated

ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT

Minimal Residual Disease | ALL, Childhood

Norway, Spain, Denmark, Austria, Belgium, Czechia, France, Italy, Poland, Slovakia
University Hospital, Ghent

Completed

The Hysteroscopic Morcellator (HM). (HM)

Large Intrauterine Polyps | Smaller Type 0 and 1 Myomas | Residual Placental Tissue

Belgium, Netherlands
Hoffmann-La Roche
NSABP Foundation Inc; German Breast Group

Active, not recruiting

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Breast Cancer

United States, Italy, United Kingdom, Canada, Czechia, Argentina, Austria, Belgium, Brazil, China, France, Germany, Guatemala, Ireland, Panama, Spain, Sweden, Taiwan, Turkey, Colombia, Hong Kong, Peru, Switzerland, South Africa, Israel, G... and more
Amgen Research (Munich) GmbH

Completed

Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) (BLAST)

B-cell Acute Lymphoblastic Leukemia

Austria, Belgium, France, Germany, Italy, Netherlands, Poland, Romania, Russian Federation, Spain, United Kingdom
Amgen

Terminated

Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)

High-risk Diffuse Large B-cell Lymphoma

United States, Italy, Belgium, Switzerland, Australia, France, Greece
Daiichi Sankyo, Inc.
AstraZeneca; NSABP Foundation Inc; German Breast Group; Spanish Breast Cancer Research...

Active, not recruiting

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

HER2-Positive Primary Breast Cancer | Residual Invasive Breast Cancer

United States, Spain, France, Germany, Korea, Republic of, United Kingdom, Denmark, Israel, Belgium, Taiwan, Chile, Italy, Japan, Peru, Portugal, China, Turkey, Canada, Ireland, Australia, Greece, Czechia, Singapore, Poland, Romania, Arge... and more

Clinical Trials on Residual in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations